238 related articles for article (PubMed ID: 22515556)
1. Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies.
Husted SE; Storey RF; Bliden K; Tantry US; Høimark L; Butler K; Wei C; Teng R; Gurbel PA
Clin Pharmacokinet; 2012 Jun; 51(6):397-409. PubMed ID: 22515556
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers.
Butler K; Teng R
Br J Clin Pharmacol; 2010 Jul; 70(1):65-77. PubMed ID: 20642549
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.
Li H; Guo J; Carlson GF; Teng R
Br J Clin Pharmacol; 2016 Aug; 82(2):352-61. PubMed ID: 27038001
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Wang H; Qi J; Li Y; Tang Y; Li C; Li J; Han Y
Br J Clin Pharmacol; 2018 Jan; 84(1):88-96. PubMed ID: 28921624
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor Versus Clopidogrel in Black Patients With Stable Coronary Artery Disease: Prospective, Randomized, Open-Label, Multiple-Dose, Crossover Pilot Study.
Waksman R; Maya J; Angiolillo DJ; Carlson GF; Teng R; Caplan RJ; Ferdinand KC
Circ Cardiovasc Interv; 2015 Jul; 8(7):e002232. PubMed ID: 26152562
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease.
Hiasa Y; Teng R; Emanuelsson H
Cardiovasc Interv Ther; 2014 Oct; 29(4):324-33. PubMed ID: 24935072
[TBL] [Abstract][Full Text] [Related]
7. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
Gurbel PA; Bliden KP; Butler K; Tantry US; Gesheff T; Wei C; Teng R; Antonino MJ; Patil SB; Karunakaran A; Kereiakes DJ; Parris C; Purdy D; Wilson V; Ledley GS; Storey RF
Circulation; 2009 Dec; 120(25):2577-85. PubMed ID: 19923168
[TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects.
Teng R; Mitchell P; Butler K
Eur J Clin Pharmacol; 2013 Apr; 69(4):877-83. PubMed ID: 23093043
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.
Teng R
Clin Pharmacokinet; 2012 May; 51(5):305-18. PubMed ID: 22489610
[TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.
Floyd CN; Passacquale G; Ferro A
Clin Pharmacokinet; 2012 Jul; 51(7):429-42. PubMed ID: 22568693
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study.
Li H; Butler K; Yang L; Yang Z; Teng R
Clin Drug Investig; 2012 Feb; 32(2):87-97. PubMed ID: 22168538
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects.
Teng R; Butler K
Eur J Clin Pharmacol; 2010 May; 66(5):487-96. PubMed ID: 20091161
[TBL] [Abstract][Full Text] [Related]
13. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses.
Storey RF; Bliden KP; Ecob R; Karunakaran A; Butler K; Wei C; Tantry U; Gurbel PA
J Thromb Haemost; 2011 Sep; 9(9):1730-7. PubMed ID: 21707911
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, pharmacodynamics, and safety of ticagrelor in volunteers with mild hepatic impairment.
Butler K; Teng R
J Clin Pharmacol; 2011 Jul; 51(7):978-87. PubMed ID: 20926753
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and pharmacodynamics of ticagrelor and AR-C124910XX in Chinese healthy male subjects.
Liu S; Xue L; Shi X; Sun Z; Zhu Z; Zhang X; Tian X
Eur J Clin Pharmacol; 2018 Jun; 74(6):745-754. PubMed ID: 29442148
[TBL] [Abstract][Full Text] [Related]
16. Effect of age and gender on pharmacokinetics and pharmacodynamics of a single ticagrelor dose in healthy individuals.
Teng R; Mitchell P; Butler K
Eur J Clin Pharmacol; 2012 Aug; 68(8):1175-82. PubMed ID: 22367426
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of ticagrelor pharmacodynamic interactions with reversibly binding or non-reversibly binding P2Y(12) antagonists in an ex-vivo canine model.
Ravnefjord A; Weilitz J; Emanuelsson BM; van Giezen JJ
Thromb Res; 2012 Oct; 130(4):622-8. PubMed ID: 22909827
[TBL] [Abstract][Full Text] [Related]
18. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic-pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients.
Åstrand M; Amilon C; Röshammar D; Himmelmann A; Angiolillo DJ; Storey RF; Gurbel PA; Bonaca MP; Hamrén B
Br J Clin Pharmacol; 2019 Feb; 85(2):413-421. PubMed ID: 30414387
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of ticagrelor in subjects on hemodialysis and subjects with normal renal function.
Teng R; Muldowney S; Zhao Y; Berg JK; Lu J; Khan ND
Eur J Clin Pharmacol; 2018 Sep; 74(9):1141-1148. PubMed ID: 29850937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
